CN110036028B - 抗il1-rap抗体 - Google Patents

抗il1-rap抗体 Download PDF

Info

Publication number
CN110036028B
CN110036028B CN201780075197.7A CN201780075197A CN110036028B CN 110036028 B CN110036028 B CN 110036028B CN 201780075197 A CN201780075197 A CN 201780075197A CN 110036028 B CN110036028 B CN 110036028B
Authority
CN
China
Prior art keywords
antibody
rap
ser
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780075197.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110036028A (zh
Inventor
蒋英萍
杰格塔·R·祖奴图拉
伦纳德·G·普雷斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantargia AB
Original Assignee
Cantargia AB
Cellerant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/055994 external-priority patent/WO2018071455A1/en
Application filed by Cantargia AB, Cellerant Therapeutics Inc filed Critical Cantargia AB
Priority claimed from PCT/US2017/056808 external-priority patent/WO2018071910A2/en
Publication of CN110036028A publication Critical patent/CN110036028A/zh
Application granted granted Critical
Publication of CN110036028B publication Critical patent/CN110036028B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780075197.7A 2016-10-16 2017-10-16 抗il1-rap抗体 Active CN110036028B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662408807P 2016-10-16 2016-10-16
US62/408,807 2016-10-16
US201662425970P 2016-11-23 2016-11-23
US62/425,970 2016-11-23
PCT/US2017/055994 WO2018071455A1 (en) 2016-10-10 2017-10-10 Isoquinolidinobenzodiazepine (iqb)-1(chloromethyl)-2,3-dihydro-1h-benzo[e]indole (cbi) dimers
USPCT/US2017/055994 2017-10-10
PCT/US2017/056808 WO2018071910A2 (en) 2016-10-16 2017-10-16 Anti-il1-rap antibodies

Publications (2)

Publication Number Publication Date
CN110036028A CN110036028A (zh) 2019-07-19
CN110036028B true CN110036028B (zh) 2023-09-08

Family

ID=67234936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075197.7A Active CN110036028B (zh) 2016-10-16 2017-10-16 抗il1-rap抗体

Country Status (6)

Country Link
US (1) US11359025B2 (enExample)
EP (1) EP3526247A4 (enExample)
JP (2) JP7032394B2 (enExample)
CN (1) CN110036028B (enExample)
AU (1) AU2017343784A1 (enExample)
CA (1) CA3084459A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
WO2020035577A1 (en) 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions
EP4013794A4 (en) * 2019-08-12 2023-11-22 City of Hope Il1rap antibodies
US11479610B2 (en) * 2020-12-23 2022-10-25 Cantargia Ab Anti-IL1RAP antibody
JP2024505674A (ja) * 2021-02-05 2024-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ１ｒａｐ抗体
AU2022215644A1 (en) * 2021-02-08 2023-06-22 Cdx Medical Ip, Inc. Dynamically prioritizing, organizing and displaying cells and tissue in order of their diagnostic significance
AU2022420026A1 (en) * 2021-12-23 2024-07-11 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
AU2022492449A1 (en) * 2022-12-29 2025-07-10 Chang Gung Memorial Hospital, Linkou Antibodies specific to transmembrane and coiled-coil domain family 3 and uses thereof
AU2024216919A1 (en) * 2023-02-09 2025-08-07 City Of Hope Anti-il1rap antibodies and variants thereof
WO2025024431A1 (en) * 2023-07-24 2025-01-30 Vanderbilt University Broadly reactive antibodies to influenza b viruses
TW202530255A (zh) * 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
CN104736562A (zh) * 2012-05-07 2015-06-24 塞勒兰特治疗公司 Cll-1特异性的抗体
WO2015132602A1 (en) * 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4811845A (en) 1987-10-06 1989-03-14 Baggett Jobeth Medication compliance packaging system and procedure
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20030007976A1 (en) 1997-12-23 2003-01-09 Watson James D. Methods and compounds for the treatment of immunologically-mediated skin disorders
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
US20150315279A1 (en) * 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
AU2017343565A1 (en) 2016-10-10 2019-05-30 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
CN104736562A (zh) * 2012-05-07 2015-06-24 塞勒兰特治疗公司 Cll-1特异性的抗体
WO2015132602A1 (en) * 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof

Also Published As

Publication number Publication date
CN110036028A (zh) 2019-07-19
JP2022091747A (ja) 2022-06-21
US11359025B2 (en) 2022-06-14
US20190338038A1 (en) 2019-11-07
AU2017343784A1 (en) 2019-08-29
JP7235904B2 (ja) 2023-03-08
JP7032394B2 (ja) 2022-03-30
EP3526247A4 (en) 2021-04-14
JP2019534705A (ja) 2019-12-05
EP3526247A2 (en) 2019-08-21
CA3084459A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
CN110036028B (zh) 抗il1-rap抗体
US10723805B2 (en) Antibodies specific for CLL-1
US11072662B2 (en) Humanized anti-CLL-1 antibodies
US10301394B2 (en) Antibodies that specifically bind to TIM3
US20150315279A1 (en) Antibodies that bind membrane-bound il1rap
WO2018071910A2 (en) Anti-il1-rap antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200427

Address after: Lund, Sweden

Applicant after: CANTARGIA AB

Address before: California, USA

Applicant before: CELLERANT THERAPEUTICS, Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant